The U.S. Food and Drug Administration approved Bristol Myers Squibb's (NYSE: BMY) Sotyktu (deucravacitinib) for treating adults with active psoriatic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE